News Column

Intercept Pharmaceuticals Appoints Rachel McMinn, Ph.D. as Chief Strategy Officer

May 5, 2014

Dr. McMinn will be responsible for leading corporate strategy and business development. She will report to Mark Pruzanski, M.D., President and CEO of Intercept, and will be a member of the Intercept management team.

"Rachel is very highly regarded in the biotechnology sector," commented Dr. Pruzanski. "Her scientific and financial background, coupled with her experience as a leading research analyst, will bring valuable strategic insight to help guide Intercept's growth and future success."?

"I am extremely excited to join Mark and the Intercept team, to build a company poised to deliver important new medicines to patients suffering from diseases with high unmet needs," said Dr. McMinn.

Dr. McMinn brings more than 13 years of biotechnology industry experience to the company. Since 2009 until joining Intercept, she was a managing director at Bank of America Merrill Lynch, working as the lead research analyst covering the biotechnology industry. Previously, Dr. McMinn worked at Cowen and Company as a lead biotechnology analyst and started her career as a biotechnology analyst at Piper Jaffray %7E Co. She earned a Bachelor of Arts degree in chemistry from Cornell University, a Ph.D. in molecular and cellular biology and chemistry from The Scripps Research Institute, and was awarded a post-doctoral Miller fellowship at the University of California, at Berkeley.

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Global Data Point

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters